ClinicalTrials.gg
CompletedNCT03088813RESILIENTUpdated Feb 19, 2025Results posted

Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer

A Phase 3 interventional study of Irinotecan liposome injection and Topotecan in Small Cell Lung Cancer, sponsored by Ipsen. Completed at 118 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-19.

Sponsored by Ipsen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
491
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 629 studies in Small Cell Lung Carcinoma with a site in United States — 111 open to participants now, 182 under way, 26 of them phase 3. Small Cell Lung Carcinoma · United States.

Enrollment
45th of 550
491 · median 55
Started
2018
with 32 others
Phase 3
50 of 629
11 open now
Registered
337th of 629
by date

Among the 629 studies in Small Cell Lung Carcinoma with a site in United States, this one is the 45th largest by enrollment of the 550 interventional ones that give a count, is one of 33 that started in 2018, is one of 50 in phase 3, and was the 337th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

111 of the 629 studies in Small Cell Lung Carcinoma with a site in United States are open now. Recruiting first, the newest first:

106 more — sign in →

All 111 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 629 studies in Small Cell Lung Carcinoma with a site in United States, or all of them as a file.
02

Study summary

A randomized, open label phase 3 study of irinotecan liposome injection (ONIVYDE®) versus topotecan in patients with small cell lung cancer who have progressed on or after platinum-based first-line therapy

The study was conducted in two parts:

  1. Dose determination of irinotecan liposome injection
  2. A randomized, efficacy study of irinotecan liposome injection versus topotecan
Read the detailed description

The study was conducted in two parts:

Part 1: Open-label dose-finding study of irinotecan liposome injection. 30 patients were planned to be enrolled.

Part 1 Primary Objectives:

  • Describe the safety and tolerability of irinotecan liposome injection monotherapy administered every 2 weeks
  • Determine the optimal irinotecan liposome injection monotherapy dose for Part 2 of this study

Part 2: A randomized, efficacy study of irinotecan liposome injection versus intravenous (IV) topotecan.

Approximately 450 patients were planned to be enrolled in part 2.

Part 2 objectives: To compare overall survival following treatment with irinotecan liposome injection with overall survival following treatment with IV topotecan.

03

Conditions studied

  • Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age.
  • Able to understand and provide an
  • (ECOG) performance status of 0 or 1.
  • >12 weeks
  • Histopathologically or confirmed small cell lung cancer
  • Evaluable disease as defined by Version 1.1 guidelines (patients with non only are eligible).
  • Radiologically confirmed progression on or after platinum based chemotherapy (carboplatin or cisplatin), or chemo-radiation including platinum-based chemotherapy for treatment of limited or extensive stage Small Cell Lung Cancer (SCLC). In addition to platinum-based regimen, one line of immunotherapy as monotherapy or in combination, in first or in second line setting is allowed.
  • Recovered from the effects of any prior chemotherapy, surgery, radiotherapy or other anti-neoplastic therapy (recovered to Grade 1 or better, with the exception of alopecia, peripheral neuropathy, or ototoxicity).
  • Adequate bone marrow reserves
  • Adequate hepatic function
  • Adequate renal function
  • during the Screening period without any findings, per investigator's assessment
  • Patients with certain types of asymptomatic that meet ALL the following criteria are eligible.

    1. Patients with asymptomatic CNS metastases prior to enrollment
    2. Prior radiation for CNS disease is completed ≥4 weeks prior to enrollment
    3. CNS metastases that are stable or have decreased according to the post radiation follow-up scan that is conducted at least 4 weeks after completion of radiation treatment for CNS lesion.
    4. Patients have discontinued or are on stable low-dose steroids (prednisone or equivalent 10 mg daily or less) for at least 1 week after completion of radiation for CNS lesion prior to enrollment.

Exclusion criteria

Exclusion Criteria

  • Any medical or social condition deemed by the Investigator to be likely to interfere with a patient's ability to sign , cooperate and participate in the study, or interfere with the interpretation of the results
  • Pregnant or breast feeding;
  • Patients with large cell neuroendocrine lung carcinoma.
  • Patients who have received prior topoisomerase I inhibitor treatment, retreatment with platinum-based regimen, antibody-drug conjugates or molecular targeted agents, more than one line of immunotherapy, or any other additional regimen of prior cytotoxic chemotherapy.
  • Patients with the symptomatic Central Nervous System (CNS) and/or who have developed new or progressive within 3 months following prophylactic and/or therapeutic cranial radiation (whole brain stereotactic radiation).
  • Patients with carcinomatous meningitis.
  • Unable to discontinue the use of strong or UGT1A1 inhibitors at least 1 week or strong CYP3A4 inducers at least 2 weeks prior to receiving the first dose of irinotecan liposome injection.
  • Have a previous or concurrent cancer that is distinct in primary (non-pulmonary) site or SCLC histology
  • therapy administered within 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is less, prior to the first scheduled day of dosing in this study.
  • Severe cardiovascular and pulmonary diseases
  • Class III or IV congestive heart failure, ventricular arrhythmias, or uncontrolled blood pressure.
  • Active infection
  • Known to any of the components of irinotecan liposome injection, other liposomal products, or topotecan.
  • gastrointestinal disorder including hepatic disorders, bleeding, inflammation, occlusion, or diarrhea > grade 1.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
491 participants (actual)

Study arms

  • Experimental
    Part 1: Experimental Arm, dose level 1

    Irinotecan liposome injection

    Drug: Irinotecan liposome injection

  • Experimental
    Part 1: Experimental Arm, dose level 2

    Irinotecan liposome injection

    Drug: Irinotecan liposome injection

  • Experimental
    Part 2: Experimental Arm

    Irinotecan liposome injection

    Drug: Irinotecan liposome injection

  • Active comparator
    Part 2: Control Arm

    Topotecan

    Drug: Topotecan

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant following or during exposure to a study treatment, whether or not causally related to the study treatment. An undesirable medical condition could be symptoms, signs or abnormal results of an investigation. An SAE was any AE that: resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability or incapacity; resulted in congenital anomaly or birth defect; or was medically important. A TEAE was any AE that occurred or worsened on or after the day of first dose of study treatment and within 30 days after discontinuation of study treatment.

    Time frame: The TEAEs were reported from the time of first study treatment administration (Day 1) up to 30 days after the date of last study treatment administration, approximately 680 days

  2. Part 1: Number of Participants With Dose-Limiting Toxicities (DLT)

    A TEAE was considered as DLT if it occurred during the safety evaluation period (i.e. first 28 days of treatment or 14 days after the second dose of study treatment if there was a treatment delay due to non-DLT related reasons) and were deemed related to the study treatment by the investigator. The determination of whether an Adverse Event was considered a Dose Limiting Toxicity was made by the Safety Review Committee (SRC) comprising the Part 1 Investigators and the Medical Monitor(s) of the Sponsor.

    Time frame: From the start of the first study treatment administration (Day 1) up to 14 days after the second dose of study treatment administration, a maximum of 42 days

  3. Part 2: Overall Survival (OS)

    The OS was defined as the time from randomization date to the date of death from any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive. The OS was calculated using Kaplan-Meier technique. Following end of treatment participant and/or family was contacted by telephone every month to assess vital status.

    Time frame: From date of randomization (within 7 days before start of study treatment) until death. Assessed up to Part 2 primary analysis DCO date of 08 February 2022 (approximately 900 days)

Secondary outcomes

  1. Part 1: Objective Response Rate (ORR)

    The ORR was defined as the percentage of participants with a best overall response (BOR) characterized as either a complete response (CR) or partial response (PR) recorded from date of first dose of study treatment until documented PD or death. ORR analysis was based on BOR using RECIST v1.1 per investigator assessment. Per RECIST v1.1, CR is disappearance of all target lesions; PR is \>=30% decrease in the sum of the longest diameter of target lesions; and overall response = CR + PR. Per protocol, participants had computed tomography (CT)-scans and brain magnetic resonance imaging (MRI) every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.

    Time frame: RECIST assessments performed at Baseline (within 28 days before start of study treatment), every 6 weeks post first dose and treatment pause, 30 days after discontinuation of study treatment, then every month thereafter, approximately maximum of 1177 days

  2. Part 1: Progression-Free Survival (PFS)

    The PFS was defined as time from first dose of study treatment to the first documented objective PD using RECIST v1.1 or death due to any cause, whichever occurs first. Per RECIST 1.1, progression is defined as at least 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. The PFS was calculated using Kaplan-Meier technique. Per protocol, participants had CT-scans and brain MRI every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.

    Time frame: RECIST assessments performed at Baseline (within 28 days before start of study treatment), every 6 weeks post first dose and treatment pause, 30 days after discontinuation of study treatment, then every month thereafter, approximately maximum of 1177 days

  3. Part 1: OS

    The OS was defined as the time from first dose of study treatment to the date of death from any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive. The OS was calculated using Kaplan-Meier technique. Following end of treatment participant and/or family was contacted by telephone every month to assess vital status.

    Time frame: From Baseline (Day 1) until death. Assessed up to Part 1 DCO date of 11 August 2021 (approximately 1177 days)

  4. Part 2: PFS

    The PFS was defined as time from randomization to first documented objective PD using RECIST 1.1 (or response assessment in neuro-oncology brain metastases \[RANO-BM\] criteria for central nervous system \[CNS\] lesions) as assessed by blinded independent central review (BICR) or death due to any cause, whichever occurred first. Per RECIST 1.1, progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. The PFS was calculated using Kaplan-Meier technique. Per protocol, participants had CT-scans and brain MRI every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.

    Time frame: RECIST assessments performed at Baseline (within 28 days before start of study treatment), every 6 weeks post first dose and treatment pause, 30 days after discontinuation of study treatment, then every month thereafter, approximately maximum of 900 days

  5. Part 2: ORR

    The ORR was defined as percentage of participants with a BOR characterized as either a CR or PR, recorded from randomization until documented PD or death relative to the total number of participants. ORR analysis was based on BOR assessed by BICR using RECIST v1.1. Per RECIST v1.1, CR is disappearance of all target lesions; PR is \>=30% decrease in the sum of the longest diameter of target lesions; and overall response = CR + PR. Per protocol, participants had CT-scans and brain MRI every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.

    Time frame: RECIST assessments performed at Baseline (within 28 days before start of study treatment), every 6 weeks post first dose and treatment pause, 30 days after discontinuation of study treatment, then every month thereafter, approximately maximum of 900 days

  6. Part 2: Median Duration of Response (DoR)

    The DoR was defined as time from the first documented objective response (CR or PR, whichever was earlier) to the date of first documented PD or death due to any cause. The DoR analysis was based on BOR assessed by BICR using RECIST v1.1. Per RECIST v1.1, CR is disappearance of all target lesions and PR is \>=30% decrease in the sum of the longest diameter of target lesions. The DoR was calculated using Kaplan-Meier technique. Per protocol, participants had CT-scans and brain MRI every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.

    Time frame: RECIST assessments performed at Baseline (within 28 days before start of study treatment), every 6 weeks post first dose and treatment pause, 30 days after discontinuation of study treatment, then every month thereafter, approximately maximum of 900 days

  7. Part 2: Median Time to Objective Response (OR)

    Time to OR as per RECIST v1.1 criteria according to BICR was defined as time from the date of randomization to the date of first documented objective tumor response (CR or PR, whichever was first). Per RECIST v1.1, CR is disappearance of all target lesions; PR is \>=30% decrease in the sum of the longest diameter of target lesion. Participants with a new anti-cancer therapy prior to OR were censored at the last tumor assessment prior to new anti-cancer therapy. Per protocol, participants had CT-scans and brain MRI every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.

    Time frame: RECIST assessments performed at Baseline (within 28 days before start of study treatment), every 6 weeks post first dose and treatment pause, 30 days after discontinuation of study treatment, then every month thereafter, approximately maximum of 900 days

  8. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30)/Lung Cancer Supplement (LC13) Dyspnea Scale at Week 12

    The EORTC QLQ-LC13 is a lung cancer specific module used in conjunction with EORTC QLQ-C30 and covers typical symptoms of lung cancer (cough, pain, dyspnea, sore mouth, peripheral neuropathy, hair loss). Scores range from 0-100 and a high score represents a high level of symptomatology/problems/worse QoL. Baseline was defined as the last non-missing measurement taken prior to reference start date. Change from baseline in dyspnea scale was calculated regardless of premature study treatment discontinuation. Participants completed these questionnaires on an electronic tablet every 6 weeks during treatment and it was continued until PD or commencement of new anti-neoplastic therapy.

    Time frame: Baseline (Day 1) and Week 12

  9. Change From Baseline in EORTC QLQ-LC13 Cough Scale at Week 12

    The EORTC QLQ-LC13 is a lung cancer specific module used in conjunction with EORTC QLQ-C30 and covers typical symptoms of lung cancer (cough, pain, dyspnea, sore mouth, peripheral neuropathy, hair loss). Score ranges from 0-100 scale and a high score represents a high level of symptomatology/problems/worse QoL. Baseline was defined as the last non-missing measurement taken prior to reference start date. Change from baseline in cough scale was calculated regardless of premature study treatment discontinuation. Participants completed these questionnaires on an electronic tablet every 6 weeks during treatment and it was continued until PD or commencement of new anti-neoplastic therapy.

    Time frame: Baseline (Day 1) and Week 12

07

Results

Posted Oct 17, 2023

Participant flow

This Phase III, 2-part (Part 1: \[open-label, single-arm dose evaluation period\] and Part 2 \[randomized, open-label period\]) study was conducted in participants with small cell lung cancer (SCLC) who progressed on or after platinum-based first-line therapy at 11 sites for Part 1 and 116 sites for Part 2 in the USA, Europe, Asia, Australia, Turkey and Brazil. First participant was enrolled on 25 April 2018 and primary analysis data cut-off (DCO) date was 08 February 2022 for Part 2.

Part 1: Dose Evaluation (Up to Week 172)
Participant flow — Part 1: Dose Evaluation (Up to Week 172)
MilestonePart 1: Irinotecan Liposome Injection 85 Milligrams/Meter Square (mg/m^2)Part 1: Irinotecan Liposome Injection 70 mg/m^2Part 2: Irinotecan Liposome Injection 70 mg/m^2Part 2: Topotecan 1.5 mg/m^2
Started52500
Completed52400
Not completed0100
Withdrew: Withdrawal by subject0100
Part 2: Randomized Study (Upto Week 197)
Participant flow — Part 2: Randomized Study (Upto Week 197)
MilestonePart 1: Irinotecan Liposome Injection 85 Milligrams/Meter Square (mg/m^2)Part 1: Irinotecan Liposome Injection 70 mg/m^2Part 2: Irinotecan Liposome Injection 70 mg/m^2Part 2: Topotecan 1.5 mg/m^2
Started00229232
Completed00202211
Not completed002721
Withdrew: Protocol violation0010
Withdrew: Investigator decision0022
Withdrew: Lost to follow-up0034
Withdrew: Withdrawal by subject001814
Withdrew: Screen failure0001
Withdrew: Other0030

Outcome measures

PrimaryPart 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)

An adverse event (AE) was any untoward medical occurrence in a participant following or during exposure to a study treatment, whether or not causally related to the study treatment. An undesirable medical condition could be symptoms, signs or abnormal results of an investigation. An SAE was any AE that: resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability or incapacity; resulted in congenital anomaly or birth defect; or was medically important. A TEAE was any AE that occurred or worsened on or after the day of first dose of study treatment and within 30 days after discontinuation of study treatment.

Time frame:
The TEAEs were reported from the time of first study treatment administration (Day 1) up to 30 days after the date of last study treatment administration, approximately 680 days
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)
ParticipantsPart 1: Irinotecan Liposome Injection 85 mg/m^2Part 1: Irinotecan Liposome Injection 70 mg/m^2
Any TEAE525
Serious TEAEs49
PrimaryPart 1: Number of Participants With Dose-Limiting Toxicities (DLT)

A TEAE was considered as DLT if it occurred during the safety evaluation period (i.e. first 28 days of treatment or 14 days after the second dose of study treatment if there was a treatment delay due to non-DLT related reasons) and were deemed related to the study treatment by the investigator. The determination of whether an Adverse Event was considered a Dose Limiting Toxicity was made by the Safety Review Committee (SRC) comprising the Part 1 Investigators and the Medical Monitor(s) of the Sponsor.

Time frame:
From the start of the first study treatment administration (Day 1) up to 14 days after the second dose of study treatment administration, a maximum of 42 days
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Dose-Limiting Toxicities (DLT)
ParticipantsPart 1: Irinotecan Liposome Injection 85 mg/m^2Part 1: Irinotecan Liposome Injection 70 mg/m^2
Part 1: Number of Participants With Dose-Limiting Toxicities (DLT)42
PrimaryPart 2: Overall Survival (OS)

The OS was defined as the time from randomization date to the date of death from any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive. The OS was calculated using Kaplan-Meier technique. Following end of treatment participant and/or family was contacted by telephone every month to assess vital status.

Time frame:
From date of randomization (within 7 days before start of study treatment) until death. Assessed up to Part 2 primary analysis DCO date of 08 February 2022 (approximately 900 days)
Reported as:
Median · months
Part 2: Overall Survival (OS)
monthsPart 2: Irinotecan Liposome Injection 70 mg/m^2Part 2: Topotecan 1.5 mg/m^2
Part 2: Overall Survival (OS)7.92 (6.87 to 9.23)8.31 (7.33 to 9.13)
Statistical analysis
  • Part 2: Irinotecan Liposome Injection 70 mg/m^2 vs Part 2: Topotecan 1.5 mg/m^2 · Stratified log-rank test · p = 0.3094 · Hazard ratio (hr): 1.11 · 95% CI 0.90 to 1.37The associated HR and two-sided 95% Confidence Interval (CI) were estimated using stratified Cox proportional hazards model, stratified by corrected region and corrected platinum sensitivity.
SecondaryPart 1: Objective Response Rate (ORR)

The ORR was defined as the percentage of participants with a best overall response (BOR) characterized as either a complete response (CR) or partial response (PR) recorded from date of first dose of study treatment until documented PD or death. ORR analysis was based on BOR using RECIST v1.1 per investigator assessment. Per RECIST v1.1, CR is disappearance of all target lesions; PR is \>=30% decrease in the sum of the longest diameter of target lesions; and overall response = CR + PR. Per protocol, participants had computed tomography (CT)-scans and brain magnetic resonance imaging (MRI) every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.

Time frame:
RECIST assessments performed at Baseline (within 28 days before start of study treatment), every 6 weeks post first dose and treatment pause, 30 days after discontinuation of study treatment, then every month thereafter, approximately maximum of 1177 days
Reported as:
Number · percentage of participants
Part 1: Objective Response Rate (ORR)
percentage of participantsPart 1: Irinotecan Liposome Injection 85 mg/m^2Part 1: Irinotecan Liposome Injection 70 mg/m^2
Part 1: Objective Response Rate (ORR)40 (5.27 to 85.34)44 (24.40 to 65.07)
SecondaryPart 1: Progression-Free Survival (PFS)

The PFS was defined as time from first dose of study treatment to the first documented objective PD using RECIST v1.1 or death due to any cause, whichever occurs first. Per RECIST 1.1, progression is defined as at least 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. The PFS was calculated using Kaplan-Meier technique. Per protocol, participants had CT-scans and brain MRI every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.

Time frame:
RECIST assessments performed at Baseline (within 28 days before start of study treatment), every 6 weeks post first dose and treatment pause, 30 days after discontinuation of study treatment, then every month thereafter, approximately maximum of 1177 days
Reported as:
Median · months
Part 1: Progression-Free Survival (PFS)
monthsPart 1: Irinotecan Liposome Injection 85 mg/m^2Part 1: Irinotecan Liposome Injection 70 mg/m^2
Part 1: Progression-Free Survival (PFS)4.19 (1.58 to NA)3.98 (2.69 to 4.24)
SecondaryPart 1: OS

The OS was defined as the time from first dose of study treatment to the date of death from any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive. The OS was calculated using Kaplan-Meier technique. Following end of treatment participant and/or family was contacted by telephone every month to assess vital status.

Time frame:
From Baseline (Day 1) until death. Assessed up to Part 1 DCO date of 11 August 2021 (approximately 1177 days)
Reported as:
Median · months
Part 1: OS
monthsPart 1: Irinotecan Liposome Injection 85 mg/m^2Part 1: Irinotecan Liposome Injection 70 mg/m^2
Part 1: OS10.84 (0.99 to NA)8.08 (5.16 to 9.82)
SecondaryPart 2: PFS

The PFS was defined as time from randomization to first documented objective PD using RECIST 1.1 (or response assessment in neuro-oncology brain metastases \[RANO-BM\] criteria for central nervous system \[CNS\] lesions) as assessed by blinded independent central review (BICR) or death due to any cause, whichever occurred first. Per RECIST 1.1, progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. The PFS was calculated using Kaplan-Meier technique. Per protocol, participants had CT-scans and brain MRI every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.

Time frame:
RECIST assessments performed at Baseline (within 28 days before start of study treatment), every 6 weeks post first dose and treatment pause, 30 days after discontinuation of study treatment, then every month thereafter, approximately maximum of 900 days
Reported as:
Median · months
Part 2: PFS
monthsPart 2: Irinotecan Liposome Injection 70 mg/m^2Part 2: Topotecan 1.5 mg/m^2
Part 2: PFS4.01 (2.96 to 4.17)3.25 (2.79 to 4.14)
Statistical analysis
  • Part 2: Irinotecan Liposome Injection 70 mg/m^2 vs Part 2: Topotecan 1.5 mg/m^2 · Stratified log-rank test · p = 0.7053 (From stratified log-rank test, stratified by corrected region and corrected platinum sensitivity) · Hazard ratio (hr): 0.96 · 95% CI 0.77 to 1.20The associated HR and two-sided 95% CI were estimated using stratified Cox proportional hazards model, stratified by corrected region and corrected platinum sensitivity.
SecondaryPart 2: ORR

The ORR was defined as percentage of participants with a BOR characterized as either a CR or PR, recorded from randomization until documented PD or death relative to the total number of participants. ORR analysis was based on BOR assessed by BICR using RECIST v1.1. Per RECIST v1.1, CR is disappearance of all target lesions; PR is \>=30% decrease in the sum of the longest diameter of target lesions; and overall response = CR + PR. Per protocol, participants had CT-scans and brain MRI every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.

Time frame:
RECIST assessments performed at Baseline (within 28 days before start of study treatment), every 6 weeks post first dose and treatment pause, 30 days after discontinuation of study treatment, then every month thereafter, approximately maximum of 900 days
Reported as:
Number · percentage of participants
Part 2: ORR
percentage of participantsPart 2: Irinotecan Liposome Injection 70 mg/m^2Part 2: Topotecan 1.5 mg/m^2
Part 2: ORR44.1 (37.57 to 50.79)21.6 (16.44 to 27.41)
Statistical analysis
  • Part 2: Irinotecan Liposome Injection 70 mg/m^2 vs Part 2: Topotecan 1.5 mg/m^2 · Cochran-Mantel-Haenszel · p = <0.0001 (ORR difference, 95% CI and P-value are obtained from the Cochran-Mantel-Haenszel test stratified by corrected region and corrected platinum sensitivity.) · Difference in orr: 22.29 · 95% CI 13.97 to 30.61
SecondaryPart 2: Median Duration of Response (DoR)

The DoR was defined as time from the first documented objective response (CR or PR, whichever was earlier) to the date of first documented PD or death due to any cause. The DoR analysis was based on BOR assessed by BICR using RECIST v1.1. Per RECIST v1.1, CR is disappearance of all target lesions and PR is \>=30% decrease in the sum of the longest diameter of target lesions. The DoR was calculated using Kaplan-Meier technique. Per protocol, participants had CT-scans and brain MRI every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.

Time frame:
RECIST assessments performed at Baseline (within 28 days before start of study treatment), every 6 weeks post first dose and treatment pause, 30 days after discontinuation of study treatment, then every month thereafter, approximately maximum of 900 days
Reported as:
Median · months
Part 2: Median Duration of Response (DoR)
monthsPart 2: Irinotecan Liposome Injection 70 mg/m^2Part 2: Topotecan 1.5 mg/m2 IV
Part 2: Median Duration of Response (DoR)4.14 (3.06 to 4.34)4.17 (2.86 to 4.76)
SecondaryPart 2: Median Time to Objective Response (OR)

Time to OR as per RECIST v1.1 criteria according to BICR was defined as time from the date of randomization to the date of first documented objective tumor response (CR or PR, whichever was first). Per RECIST v1.1, CR is disappearance of all target lesions; PR is \>=30% decrease in the sum of the longest diameter of target lesion. Participants with a new anti-cancer therapy prior to OR were censored at the last tumor assessment prior to new anti-cancer therapy. Per protocol, participants had CT-scans and brain MRI every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.

Time frame:
RECIST assessments performed at Baseline (within 28 days before start of study treatment), every 6 weeks post first dose and treatment pause, 30 days after discontinuation of study treatment, then every month thereafter, approximately maximum of 900 days
Reported as:
Median · months
Part 2: Median Time to Objective Response (OR)
monthsPart 2: Irinotecan Liposome Injection 70 mg/m^2Part 2: Topotecan 1.5 mg/m^2
Part 2: Median Time to Objective Response (OR)1.68 (1.51 to 4.11)12.65 (8.41 to NA)
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30)/Lung Cancer Supplement (LC13) Dyspnea Scale at Week 12

The EORTC QLQ-LC13 is a lung cancer specific module used in conjunction with EORTC QLQ-C30 and covers typical symptoms of lung cancer (cough, pain, dyspnea, sore mouth, peripheral neuropathy, hair loss). Scores range from 0-100 and a high score represents a high level of symptomatology/problems/worse QoL. Baseline was defined as the last non-missing measurement taken prior to reference start date. Change from baseline in dyspnea scale was calculated regardless of premature study treatment discontinuation. Participants completed these questionnaires on an electronic tablet every 6 weeks during treatment and it was continued until PD or commencement of new anti-neoplastic therapy.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Mean · scores on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30)/Lung Cancer Supplement (LC13) Dyspnea Scale at Week 12
scores on a scalePart 2: Irinotecan Liposome Injection 70 mg/m^2Part 2: Topotecan 1.5 mg/m^2
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30)/Lung Cancer Supplement (LC13) Dyspnea Scale at Week 124.6 ± 20.741.9 ± 19.17
SecondaryChange From Baseline in EORTC QLQ-LC13 Cough Scale at Week 12

The EORTC QLQ-LC13 is a lung cancer specific module used in conjunction with EORTC QLQ-C30 and covers typical symptoms of lung cancer (cough, pain, dyspnea, sore mouth, peripheral neuropathy, hair loss). Score ranges from 0-100 scale and a high score represents a high level of symptomatology/problems/worse QoL. Baseline was defined as the last non-missing measurement taken prior to reference start date. Change from baseline in cough scale was calculated regardless of premature study treatment discontinuation. Participants completed these questionnaires on an electronic tablet every 6 weeks during treatment and it was continued until PD or commencement of new anti-neoplastic therapy.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Mean · scores on a scale
Change From Baseline in EORTC QLQ-LC13 Cough Scale at Week 12
scores on a scalePart 2: Irinotecan Liposome Injection 70 mg/m^2Part 2: Topotecan 1.5 mg/m^2
Change From Baseline in EORTC QLQ-LC13 Cough Scale at Week 121.6 ± 25.77-1.2 ± 27.31

Adverse events

Collected over The TEAEs were reported from the time of first study treatment administration (Day 1) up to 30 days after the date of last study treatment administration, approximately 680 days for Part 1 and 1452 days for Part 2. All-Cause Mortality: approximately 1919 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Irinotecan Liposome Injection 85 mg/m^25/5 (100%)4/5 (80%)5/5 (100%)
Part 1: Irinotecan Liposome Injection 70 mg/m^223/25 (92%)9/25 (36%)25/25 (100%)
Part 2: Irinotecan Liposome Injection 70 mg/m^2201/226 (88.9%)106/226 (46.9%)212/226 (93.8%)
Part 2: Topotecan 1.5 mg/m^2205/223 (91.9%)88/223 (39.5%)220/223 (98.7%)
Most frequent serious events
Showing 10 of 109
Most frequent serious events
EventPart 1: Irinotecan Liposome Injection 85 mg/m^2Part 1: Irinotecan Liposome Injection 70 mg/m^2Part 2: Irinotecan Liposome Injection 70 mg/m^2Part 2: Topotecan 1.5 mg/m^2
PneumoniaInfections and infestations2/52/2516/2267/223
Cardiac arrestCardiac disorders1/50/250/2260/223
Ectopic antidiuretic hormone secretionEndocrine disorders1/50/250/2260/223
DiarrhoeaGastrointestinal disorders1/51/2519/2261/223
NauseaGastrointestinal disorders1/50/252/2263/223
VomitingGastrointestinal disorders1/50/253/2263/223
HepatotoxicityHepatobiliary disorders1/50/250/2260/223
Liver function test abnormalInvestigations1/50/250/2260/223
HyponatraemiaMetabolism and nutrition disorders1/50/251/2265/223
Superior vena cava syndromeVascular disorders1/50/250/2261/223
Most frequent other events
Showing 10 of 66
Most frequent other events
EventPart 1: Irinotecan Liposome Injection 85 mg/m^2Part 1: Irinotecan Liposome Injection 70 mg/m^2Part 2: Irinotecan Liposome Injection 70 mg/m^2Part 2: Topotecan 1.5 mg/m^2
DiarrhoeaGastrointestinal disorders5/522/25128/22643/223
Decreased appetiteMetabolism and nutrition disorders4/510/2581/22643/223
AnaemiaBlood and lymphatic system disorders2/57/2582/226177/223
NeutropeniaBlood and lymphatic system disorders3/54/2541/226137/223
NauseaGastrointestinal disorders3/511/2596/22658/223
ArthralgiaMusculoskeletal and connective tissue disorders3/51/2511/22616/223
ThrombocytopeniaBlood and lymphatic system disorders0/54/2511/226131/223
LeukopeniaBlood and lymphatic system disorders0/50/2529/22694/223
Abdominal painGastrointestinal disorders2/55/2541/2268/223
ConstipationGastrointestinal disorders2/53/2529/22635/223

Baseline characteristics

Part 1: Safety population included all enrolled participants who were treated with at least 1 dose of irinotecan liposome injection. Part 2: Intent-to-Treat (ITT) population included all randomized participants.

Age, Customized
Age, Customized(Participants)Part 1: Irinotecan Liposome Injection 85 mg/m^2Part 1: Irinotecan Liposome Injection 70 mg/m^2Part 2: Irinotecan Liposome Injection 70 mg/m^2Part 2: Topotecan 1.5 mg/m^2Total
<65 years418128151301
>=65 years1710181190
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Irinotecan Liposome Injection 85 mg/m^2Part 1: Irinotecan Liposome Injection 70 mg/m^2Part 2: Irinotecan Liposome Injection 70 mg/m^2Part 2: Topotecan 1.5 mg/m^2Total
Female2167969166
Male39150163325
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: Irinotecan Liposome Injection 85 mg/m^2Part 1: Irinotecan Liposome Injection 70 mg/m^2Part 2: Irinotecan Liposome Injection 70 mg/m^2Part 2: Topotecan 1.5 mg/m^2Total
American Indian or Alaska Native00011
Asian00373673
Black or African American00448
White525184182396
Not Reported004913
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: Irinotecan Liposome Injection 85 mg/m^2Part 1: Irinotecan Liposome Injection 70 mg/m^2Part 2: Irinotecan Liposome Injection 70 mg/m^2Part 2: Topotecan 1.5 mg/m^2Total
Hispanic or Latino026917
Not Hispanic or Latino520214218457
Not Reported/Unknown039517
08

Study locations

118 sites
  • National Jewish Health
    Denver, Colorado 80206, United States
  • Rocky Mountain Cancer Centers
    Denver, Colorado 80218, United States
  • Florida Cancer Specialists (South Region)
    Fort Myers, Florida 33916, United States
  • Florida Cancer Specialists
    Saint Petersburg, Florida 33705, United States
  • Northwest Georgia Oncology Centers
    Marietta, Georgia 30060, United States
  • Cancer Treatment Centers of America-Georgia
    Newnan, Georgia 30265, United States
  • Illinois Cancer Care, PC
    Peoria, Illinois 61615, United States
  • Southern Maine Health Care
    Biddeford, Maine 04005, United States
  • University of Maryland Medical Group
    Baltimore, Maryland 21201, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Cancer & Hematology Centers of Western Michigan
    Grand Rapids, Michigan 49503, United States
  • Sparrow Regional Cancer Center
    Lansing, Michigan 48219, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • North Shore Hematology Oncology Associates, PC
    East Setauket, New York 11733, United States
  • Case Western Reserve University
    Cleveland, Ohio 44106, United States
  • Tri County Hematology & Oncology Associates, Inc
    Massillon, Ohio 44646, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Charleston Hematology Oncology Associates, PA
    Charleston, South Carolina 29414, United States
  • Greenville Hospital System University Medical Center
    Greenville, South Carolina 29605, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • MultiCare Health System Institute for Research and Innovation
    Spokane, Washington 99204, United States
  • Summit Cancer Treatment Center
    Spokane, Washington 99208, United States
  • Border Medical Oncology Research Unit
    Albury, New South Wales 2640, Australia
  • South West Healthcare
    Warrnambool, Victoria 3280, Australia
  • Southern Medical Day Care Centre
    Wollongong, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Australia
  • AZ Klina
    Brasschaat, Belgium
  • UZ Leuven
    Leuven, Belgium
  • Centre Hospitalier de l'Ardenne
    Libramont, Belgium
  • AZ Sint-Maarten
    Mechelen, Belgium
  • Hospital de Cancer de Barretos, Fundacoa Pio X II
    Barretos, Brazil
  • Hospital de Caridade de Ijuí
    Ijuí, Brazil
  • Oncobio Servicos de Saude
    Nova Lima, Brazil
  • HGB - Hospital Giovanni Battista - Mãe de Deus Center
    Porto Alegre, Brazil
  • Hospital Nossa Senhora da Conceição
    Porto Alegre, Brazil
  • INCA - Instituto Nacional de Câncer
    Rio De Janeiro, Brazil
  • CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
    Santo André, Brazil
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto
    São José Do Rio Preto, Brazil
  • Beijing Cancer Hospital
    Beijing, 100142, China
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, 233004, China
  • The First Hospital of Jilin University
    Changchun, 450008, China
  • West China Hospital, Sichuan University
    Chengdu, 610041, China
  • Guangdong Provincial People's Hospital
    Guangzhou, 510080, China
  • Zhejiang Cancer Hospital
    Hangzhou, 310022, China
  • Tongji Hospital
    Hubei, 430030, China
  • Linyi Cancer Hospital
    Linyi, China
  • Henan Cancer Hospital
    Zhengzhou, China
  • CHU Brest - Hôpital Morvan
    Brest, France
  • Hôpital Nord - CHU Marseille
    Marseille, France
  • Institut de Cancérologie de la Loire
    Saint-Priest-en-Jarez, France
  • Centre Hospitalier de Saint-Quentin
    Saint-Quentin, 02321, France
  • Universitaetsklinikum Freiburg
    Freiburg, 79106, Germany
  • Evangelisches Krankenhaus Hamm GmbH
    Hamm, 50063, Germany
  • Universitaetsklinikum Heidelberg
    Heidelberg, 69126, Germany
  • Pius-Hospital Oldenburg
    Oldenburg, 26121, Germany
  • Semmelweis Egyetem
    Budapest, Hungary
  • Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza
    Gyula, Hungary
  • Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet
    Szolnok, Hungary
  • Tudogyogyintezet Torokbalint
    Törökbálint, Hungary
  • Zala Megyei Szent Rafael Korhaz
    Zalaegerszeg, Hungary
  • Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori
    Meldola, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milano, Italy
  • Azienda Sanitaria Universitaria Integrata di Udine
    Udine, Italy
  • Chungbuk National University Hospital
    Cheongju-si, Korea, Republic of
  • Asan Medical Center
    Seoul, Korea, Republic of
  • The Catholic University of Korea, Seoul St. Mary's Hospital
    Seoul, Korea, Republic of
  • The Catholic University of Korea, St. Vincent's Hospital
    Suwon, Korea, Republic of
  • KO-MED Centra Kliniczne Biala Podlaska
    Biała Podlaska, Poland
  • Szpitale Pomorskie spółka z ograniczoną odpowiedzialnością
    Gdynia, Poland
  • SP Zespol Gruzlicy i Chorob Pluc w Olsztynie
    Olsztyn, Poland
  • Przychodnia Med-Polonia Sp. z o.o.
    Poznań, Poland
  • Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego
    Poznań, Poland
  • S.C Gral Medical S.R.L
    Bucuresti, Romania
  • Institutul Oncologic "Prof. Dr. Ion Chiricuta" Cluj-Napoca
    Cluj-Napoca, Romania
  • S.C Medisprof S.R.L
    Cluj-Napoca, Romania
  • S.C Centrul de Oncologie Sf. Nectarie S.R.L
    Craiova, Romania
  • S.C Radiotherapy Center Cluj S.R.L
    Floreşti, Romania
  • Oncomed SRL
    Timişoara, Romania
  • SBIH of Arkhangelsk region "Arkhangelsk Clinical Oncological Dispensary"
    Arkhangel'sk, Russian Federation
  • "VitaMed" LLC
    Moscow, Russian Federation
  • BHI of Omsk region "Clinical Oncology Dispensary"
    Omsk, Russian Federation
  • SBHI of Kaluga Region "Kaluga regional clinical oncology dispensary"
    Saint Petersburg, 197022, Russian Federation
  • SPb SBIH "City Clinical Oncological Dispensary"
    Saint Petersburg, Russian Federation
  • SBIH of Yaroslavl region "Regional Clinical Oncological Hospital"
    Yaroslavl, Russian Federation
  • Clinical Center "Bezanijska kosa"
    Belgrade, Serbia
  • Oncomed System
    Belgrade, Serbia
  • Clinical Center Kragujevac
    Belgrad, Serbia
  • Institute for Pulmonary Diseases of Vojvodina
    Sremska Kamenica, Serbia
  • General Hospital Uzice
    Užice, 31000, Serbia
  • ICO l'Hospitalet - Hospital Duran i Reynals
    L'Hospitalet De Llobregat, Barcelona 08908, Spain
  • Hospital General Universitario de Alicante
    Alicante, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital General Universitario Gregorio Marañon
    Madrid, Spain
  • Hospital Regional Universitario de Malaga
    Málaga, 29010, Spain
  • Hospital Universitario Virgen del Rocio
    Sevilla, 41013, Spain
  • Hospital Universitari i Politecnic La Fe
    Valencia, 46026, Spain
  • Changhua Christian Hospital
    Changhua, Taiwan
  • Kaohsiung Chang Gung Memorial Hospital
    Kaohsiung, Taiwan
  • National Taiwan University Hospital
    Taipei, 100, Taiwan

Showing the first 100 of 118 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Paz-Ares L, Spigel DR, Chen Y, Jove M, Juan-Vidal O, Rich P, Hayes T, Calderon VG, Caro RB, Navarro A, Dowlati A, Zhang B, Moore Y, Yao X, Kokhreidze J, Ponce S, Bunn PA. RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer. Cancer. 2022 May 1;128(9):1801-1811. doi: 10.1002/cncr.34123. Epub 2022 Feb 23. PubMed 35195913 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Feb 2022, 45 months.

Results were first posted in Oct 2023, 1 year 8 months after primary completion. A results delay was requested in Jan 2023.

Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's 45 months is above that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2017
First posted
Mar 23, 2017
StartActual
Apr 25, 2018
Primary completionActual
Feb 8, 2022
CompletionActual
Jul 27, 2023
Results delay requested
Jan 31, 2023
Results first posted
Oct 17, 2023
Last update
Feb 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03088813
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Mar 23, 2017
Start date
Apr 25, 2018
Primary completion
Feb 8, 2022
Completion
Jul 27, 2023
Results posted
Oct 17, 2023
Last update
Feb 19, 2025

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Irinotecan sucrosofate

Start the discussion